Ketone Labs & Blue Pacific Flavors Announce Strategic Partnership to Drive Innovation in goBHB Powered Functional Beverages at Expo West 2025
CITY OF INDUSTRY, Calif., March 3, 2025 /PRNewswire/ -- Ketone Labs, a leader in beta-hydroxybutyrate (BHB) innovation, has partnered with Blue Pacific Flavors, a premier expert in natural flavor solutions, to pioneer goBHB-powered functional beverages & nutritional products.
These groundbreaking non-stimulant energy beverages featuring goBHB, offer clean, sustained energy without caffeine or taurine.
The innovative beverage concept products are designed to support:
- Brain Health – Since goBHB fuels cognitive function and improves mental clarity & focus- Gut Health- By being formulated to align with microbiome-supportive ingredients, and- Metabolic Energy- By providing a rapid efficient fuel source to enhance endurance & performance.
This partnership brings together Ketone Labs' patented goBHB technology with Blue Pacific's deep expertise in flavor science and beverage formulation, creating cutting-edge solutions tailored to modern consumer demands for metabolic health, cognitive performance, and sustained energy.
Experience the Future of Functional Ketones at Expo West- Booth #4373 to sample a groundbreaking non-stimulant energy beverage featuring goBHB.
Several exclusive unique & innovative flavored products, developed by Blue Pacific Flavors will debut at Expo West 2025, showcasing how science-backed formulation meets best-in-class taste for superior consumer experiences.
Industry veteran Donald F. Wilkes, Founder & CEO of Blue Pacific Flavors, will be at Expo West 2025, along with his team, to guide attendees through these latest advancements in functional beverage innovation.
"In my 40+ years in the industry, I have never seen a technology as transformative as goBHB®," said Wilkes. "It's a game-changer in metabolic health, offering a science-backed, clean-energy solution that fits today's functional beverage landscape. Our partnership with Ketone Labs allows us to deliver the next generation of delicious, effective, and innovative products."
Rob C. Rogers, Founder of Ketone Labs, echoed this excitement:
"goBHB® is revolutionizing the industry, and our partnership with Blue Pacific Flavors is a pivotal step in unlocking its full potential. By merging our expertise in goBHB® formulation with Blue Pacific's mastery of flavor and beverage innovation, we are setting a new gold standard for functional nutrition."
Why goBHB®? goBHB® is a scientifically validated, efficient energy source that is reshaping the health and wellness space. Its key benefits include:
- Sustained Energy & Endurance – A clean fuel alternative for athletes, biohackers, and active individuals.- Cognitive & Mental Performance – Supports brain function, focus, and clarity.- Weight & Metabolic Management – Encourages ketosis without strict dietary restrictions.
About Ketone Labs - Ketone Labs is a global leader in BHB production and innovation, pioneering patented goBHB® technologies and specialized formulations that power the next generation functional beverages and metabolic health products.
About Blue Pacific Flavors - For over 32 years, Blue Pacific Flavors has been a trusted provider of natural, functional, and clean-label flavor innovations, developing world-class solutions for leading food, beverage, and nutrition brands.
Join us at Expo West – Booth #4373 to experience the future of goBHB® and flavor innovation firsthand!
For more information, press only:
Courtney Key
Adrian Lopez
courtney@ketonelabs.com
adrian@bpflavors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ketone-labs--blue-pacific-flavors-announce-strategic-partnership-to-drive-innovation-in-gobhb-powered-functional-beverages-at-expo-west-2025-302390741.html
SOURCE Blue Pacific Flavors
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
26 minutes ago
- Associated Press
HitPaw 5th Anniversary – Let's Celebrate Together! Up to 60% Off Sale
NEW YORK, N.Y., Aug. 18, 2025 (SEND2PRESS NEWSWIRE) — HitPaw, a leading innovator in AI-driven creative tools, is celebrating its 5th anniversary with a global celebration and exclusive discounts from August 15 to August 31, 2025. Whether you're a content creator, a digital artist, or just exploring AI-powered creativity, HitPaw's anniversary sale is the perfect time to upgrade your toolkit and join millions of users worldwide in celebrating five years of smart, accessible creation. This milestone event offers up to 60% off on HitPaw's most popular software, including AI video enhancers, photo upscalers, and voice changers. Offers Exclusive for Anniversary – August 15 to 31 ONLY SINGLE PRODUCTS – 30% OFF P.S. – All of above license is yearly 2.60% OFF BUNDLES – LESS COST, MORE WORTH Not interested? Check here to know more and you won't be let down. WHY CHOOSE HITPAW? From elevating product videos to restoring cherished photos and having fun with AI effects, HitPaw's 5th Anniversary is all about empowering creativity. Whether you're a content creator, a small business owner, or just someone who loves to explore digital tools, there's something for everyone in this celebration: MAKE THE 5TH ANNIVERSARY A HISTORIC ONE For five years, HitPaw has been making AI creativity more accessible—and we're just getting started. This anniversary isn't just a milestone—it's an invitation to unlock your potential, explore new tools, and create with confidence. With up to 60% off, now's the time to join millions of users worldwide in celebrating smarter creation. Learn more and shop the sale: ABOUT HITPAW HitPaw develops powerful yet easy-to-use AI software for editing videos, enhancing images, transforming audio, and more. Serving millions of creators worldwide, HitPaw empowers everyone—from casual users to professionals—to express ideas visually and audibly without complexity. To explore more creative tools, you may visit: Our Social Media: YouTube: X (Twitter): Instagram: Pinterest: NEWS SOURCE: HitPaw Keywords: Software, HitPaw 5th Anniversary Sale, NEW YORK, N.Y. This press release was issued on behalf of the news source (HitPaw) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P128539 APNF0325A To view the original version, visit: © 2025 Send2Press® Newswire, a press release distribution service, Calif., USA. RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
Yahoo
an hour ago
- Yahoo
$1M Lottery Powerball ticket won in Pa.
(WBRE/WYOU) — A lucky lottery player has won $1 million off a Powerball ticket in Pennsylvania. A Pennsylvania Lottery retailer in Carbon County sold a Powerball® ticket worth $1 million for the Monday, August 4, drawing. The ticket matched five of the five white balls drawn, 8-9-19-31-38, but not the red Powerball® 21, to win $1 million. $1M won off $20 lottery scratch-off ticket in Pa. Boyer's Food Markets in Lansford Boro will receive a $5,000 bonus for selling the winning ticket. Winners are not known until prizes are claimed and tickets are validated. Pennsylvania Lottery Powerball® winners have one year from the drawing date to claim prizes. Winning tickets purchased at a Lottery retailer should immediately be signed on the back. Online winnings automatically appear in a player's account after the claim has been processed. Players may visit for more information about how to file a claim. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI). Managing blood pressure instability is a major unmet need after SCI, with a significant impact on cardiovascular health and quality of life. Approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe are expected to participate. EINDHOVEN, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption for the ARC-IM System. With this approval, the Company can initiate the Empower BP pivotal study to assess the safety and efficacy of its implantable spinal stimulation system to address blood pressure instability after SCI. Empower BP is the Company's second global pivotal study, and the first to evaluate the implantable ARC-IM System. The randomized, double-blinded, sham-controlled study is expected to involve approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe, with first patient enrollment anticipated before the end of the year. The study will target participants with injuries at spinal cord levels C2-T6, injury severities of AIS A-D, and blood pressure instability characterized by chronic orthostatic hypotension (OH) and episodes of autonomic dysreflexia (AD). 'This is an important milestone for ONWARD and the SCI community,' said Dave Marver, CEO of ONWARD. 'Our ARC-IM System is designed to address several unmet needs, including blood pressure instability which is a major recovery target after spinal cord injury. With this IDE approval, we continue to advance our innovation pipeline and inspire realistic hope in restoring autonomic functions and independence after SCI and other movement disabilities.' Over 50% of people with SCI experience blood pressure instability, affecting nearly 350,000 people in the US and Europe.1 Blood pressure instability and persistent low blood pressure can threaten neurological recovery and negatively impact cardiovascular health and quality of life. The most frequent symptoms include dizziness, lightheadedness, blurred vision and fatigue.2 'Blood pressure instability, especially chronic low blood pressure, is one of the most hidden and unrecognized functional complications of spinal cord injury,' explains Dr. James Guest, neurosurgeon and Professor of Neurological Surgery at the University of Miami. 'It leaves people feeling unwell and can significantly impact their overall quality of life. Blood pressure instability also increases the risk of cardiovascular disease, making addressing this unmet need critical for improving the long-term outcomes of SCI.' The ONWARD ARC-IM System is an implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation. It is the first neuroprosthetic system designed to manage blood pressure instability in people with SCI. It comprises the implanted ONWARD Neurostimulator (IPG) and the ARC-IM Thoracic Lead. The ARC-IM Thoracic Lead is optimized for surgical placement in a specific region of the thoracic spinal cord, called the 'Hemodynamic Hotspot'. The location was first discovered by the Company's research partners at the Swiss Federal Institute of Technology Lausanne (EPFL), Centre Hospitalier Universitaire Vaudois (CHUV), and the University of Calgary in a study published in Nature in January 2021.3 In December 2022, the Company announced positive top-line interim clinical results from its feasibility studies showing improved blood pressure regulation and improved hemodynamic stability after SCI. In addition to immediate and sustained improved blood pressure levels, participants taking anti-hypotension drugs prior to the study significantly reduced or discontinued their medication. Participants also reported improved general well-being and a reduction in orthostatic hypotension, including reduced dizziness and increased energy. Detailed interim results from these studies are expected to be published later this year. Managing blood pressure instability is among the major unmet needs for which the FDA has awarded the Company one of its 10 Breakthrough Device Designations. This award is reserved for novel, cutting-edge therapies addressing unmet needs and provides potential regulatory and reimbursement benefits. To stay informed about ONWARD's research studies, technologies, and the availability of therapies in your area, please complete this webform. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries, and other movement disabilities. Building on over a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed ARC Therapy. It has subsequently been awarded 10 Breakthrough Device designations from the FDA. The Company's ARC-EX® System is cleared for commercial sale in the US. The Company is also developing an investigational implantable system called ARC-IM, which can be paired with a brain-computer interface (BCI) to restore thought-driven movement. Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, please visit For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Notes and references: 1. Katzelnick CG et al. Blood Pressure Instability in Persons With SCI: Evidence From a 30-Day Home Monitoring Observation. Am J Hypertens. 2019 Sep 24;32(10):938-944 2. Carlozzi, N. E. et al. Impact of blood pressure dysregulation on health-related quality of life in persons with spinal cord injury: development of a conceptual model. Arch. Phys. Med. Rehabil. 94, 1721–1730 (2013) 3. Squair, J.W. et al. Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury. Nature 590, 308–314 (2021) Forward-Looking Statements Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
